Assessment of metagenomic Nanopore and Illumina sequencing for recovering whole genome sequences of chikungunya and dengue viruses directly from clinical samples

Liana E. Kafetzopoulou 1-4, Kyriakos Efthymiadis 5, Kuiama Lewandowski 6, Ant Crook 1, Dan Carter 1, Jane Osborne 4, Emma Aarons 4, Roger Hewson 1-7, Julian A. Hiscox 1-4, Miles W. Carroll 1,2, Richard Vipond 1,2, Steven T. Pullan 1,2

1. Public Health England, National Infections Service, Porton Down, United Kingdom
2. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, United Kingdom
3. Artificial Intelligence Laboratory, Vrije Universiteit Brussel, Brussels, Belgium
4. Rare and Imported Pathogens Laboratory, Public Health England, Porton Down, United Kingdom
5. Institute of Infection and Global Health, University of Liverpool, United Kingdom

Correspondence: Steven Pullan (steven.pullan@phe.gov.uk)

Citation style for this article:
Kafetzopoulou Liana E., Efthymiadis Kyriakos, Lewandowski Kuiama, Crook Ant, Carter Dan, Osborne Jane, Aarons Emma, Hewson Roger, Hiscox Julian A., Carroll Miles W., Vipond Richard, Pullan Steven T. Assessment of metagenomic Nanopore and Illumina sequencing for recovering whole genome sequences of chikungunya and dengue viruses directly from clinical samples. Euro Surveill. 2018;23(50):pii=1800228. https://doi.org/10.2807/1560-7917.ES.2018.23.50.1800228

Background: The recent global emergence and re-emergence of arboviruses has caused significant human disease. Common vectors, symptoms and geographical distribution make differential diagnosis both important and challenging. Aim: To investigate the feasibility of metagenomic sequencing for recovering whole genome sequences of chikungunya and dengue viruses from clinical samples. Methods: We performed metagenomic sequencing using both the Illumina MiSeq and the portable Oxford Nanopore MinION on clinical samples which were real-time reverse transcription-PCR (qRT-PCR) positive for chikungunya (CHIKV) or dengue virus (DENV), two of the most important arboviruses. A total of 26 samples with a range of representative clinical Ct values were included in the study. Results: Direct metagenomic sequencing of nucleic acid extracts from serum or plasma without viral enrichment allowed for virus identification, subtype determination and elucidated complete or near-complete genomes adequate for phylogenetic analysis. One PCR-positive CHIKV sample was also found to be coinfected with DENV. Conclusions: This work demonstrates that metagenomic whole genome sequencing is feasible for the majority of CHIKV and DENV PCR-positive patient serum or plasma samples. Additionally, it explores the use of Nanopore metagenomic sequencing for DENV and CHIKV, which can likely be applied to other RNA viruses, highlighting the applicability of this approach to front-line public health and potential portable applications using the MinION.

Introduction
Arboviruses are predominantly RNA viruses that replicate in haematophagous (blood-sucking) arthropod vectors such as ticks, mosquitoes and other biting flies to maintain their transmission cycle [1]. Human disease outbreaks caused by arboviruses have increased in prevalence since the 2000’s, led by the spread of mosquito-borne arboviruses such as chikungunya (CHIKV), dengue (DENV), West Nile (WNV), yellow fever (YFV) and Zika (ZIKV) viruses across both hemispheres [2]. CHIKV and DENV are of particular global health concern, as they have lost the need for enzootic amplification and consequently have caused extensive epidemics [3].

CHIKV is a single-stranded positive-sense RNA virus of the alphavirus genus, which causes the debilitating arthritic disease, chikungunya [4]. It has spread globally and been designated a serious emerging disease by the World Health Organization [5]. Outbreaks of CHIKV since 2005 have been associated with increased morbidity and possibly mortality [6,7].

DENV, which causes dengue, is a single-stranded positive-sense RNA virus of the flavivirus genus and the most prevalent human arboviral pathogen. Dengue occurs following infection with one of four DENV serotypes (DENV1–4). A minority of cases develop acute haemorrhagic manifestations and multi-organ failure. Despite DENV cases being under-reported, a 143.1% increased global incidence was estimated between 2005 and 2015 [8]. Approximately 500,000 DENV infected patients worldwide require hospitalisation annually [9].
Both CHIKV and DENV are predominantly transmitted to humans via *Aedes* species mosquitoes, particularly *Ae. aegypti* and *Ae. albopictus* [10,11], and share clinical presentations of arthralgia, headache, high fever, myalgia and rash. Circulation of CHIKV, DENV (and other arboviruses) in the same areas leads to challenges in differential diagnosis, especially in endemic regions in which diagnosis is predominantly symptom-based [12]. Additionally, reports of arboviral coinfections are increasingly common [13-16].

Metagenomic RNA sequencing allows for identification of multiple pathogens within a sample in a non-targeted and unbiased manner. It has identified causative agents in outbreaks, e.g. Lujo virus in South Africa [17], Bundibugyo ebolavirus in Uganda [18] and lead to novel virus discovery such as a rhabdovirus causing haemorrhagic fever in central Africa [19]. It also provides genomic information for typing and surveillance. Real-time genomic surveillance was facilitated on-site by the portable Oxford Nanopore MinION sequencer during the 2014–16 Ebola virus (EBOV) epidemic in West Africa and the 2015-16 ZIKV outbreak in the Americas [20-23] for epidemiological and transmission chain investigations [24]. In both examples, an amplicon sequencing approach was used, but viruses and bacteria from clinical, environmental and vector samples have been sequenced using metagenomic approaches on the MinION [25-28]. Metagenomic sequencing of CHIKV was demonstrated in principle on the MinION by Greninger et al. in 2015 reporting the detection of CHIKV from a human blood sample [28]. Additionally, Illumina-based metagenomics identified CHIKV coinfections within a ZIKV sample cohort [29], with the high proportion of CHIKV reads present making it a promising target for the approach.

In this study we set out to test the feasibility of direct metagenomic sequencing of DENV and CHIKV genomes from a cohort of clinical serum and plasma samples across a representative range of viral loads. The objective was to assess the proportion of viral nucleic acid relative to patient/background present in each sample and determine the sequencing limits for whole genome retrieval using both the laboratory-based Illumina technology and the portable MinION platform.

**Methods**

**Sample collection and nucleic acid extraction**

Twenty-six routine diagnostic samples, nine plasma and 17 serum, were obtained from the Rare and Imported Pathogens Laboratory (RIPL), Public Health England (PHE), Porton Down. All had previously tested positive by real-time reverse transcription-PCR (qRT-PCR) for chikungunya or dengue virus, with a maximum cut-off value of cycle threshold (Ct) 35. These samples had been selected based on their Ct values, among a larger set of 441 samples, so as to represent a Ct clinical range. Total nucleic acid was extracted from 140 μL of each using the QIAamp viral RNA kit (Qiagen, Hilden, Germany) replacing carrier RNA with linear polyacrylamide and eluting in 60 μL elution buffer provided in the kit, followed by treatment with TURBO DNase (Thermo Fisher Scientific, Waltham, United States (US)) at 37°C for 30 min. RNA was purified and concentrated to 8 μL using the RNA Clean and Concentrator-5 kit (Zymo Research, Irvine, US).

**Molecular confirmation and quantification**

Drosten et al. [30] and Edwards et al. [31] RT-PCR assays were used for confirmation of DENV and CHIKV respectively. RNA oligomers were used as standards for genome copy quantitation.
Metagenomic cDNA reparation

Complementary DNA (cDNA) was prepared using a Sequence Independent Single Primer Amplification (SISPA) approach adapted from Greninger et al. [28]. Reverse transcription and second strand cDNA synthesis were as described [28]. cDNA amplification was performed using AccuTaq LA (Sigma, Poole, United Kingdom), in which 5μL of cDNA and 1 μL (100 pmol/μL) Primer B (5'-GTTTCCCACTGGAGGATA-3') were added to a 50 μL reaction, according to manufacturer’s instructions. PCR conditions were 98 °C for 30s, followed by 30 cycles of 94 °C for 15 s, 50 °C for 20 s, and 68 °C for 5 min, and a final step of 68 °C for 10 min. Amplified cDNA was purified using a 1:1 ratio of AMPure XP beads (Beckman Coulter, Brea, California (CA)) and quantified using the Qubit High Sensitivity dsDNA kit (Thermo Fisher, Waltham, US).

MinION library preparation and sequencing

MinION sequencing libraries were prepared using total amplified cDNA of each sample to a maximum of 1 µg. Oxford Nanopore kits SQK-NSK007 or SQK-LSK208 (2D), SQK-LSK308 (1D 2) and SQK-RBK001 (Rapid) were used and each sample was run individually on the appropriate flow cell (FLO-MIN105, FLO-MIN106 or FLO-MIN107) using the 48hr run script. Base calling was performed using Metrichor (ONT) for SQK-NSK007 and SQK-LSK208 or Albacore v1.2 for SQK-LSK308 and SQK-RBK001. Poretools [32] was used to extract FASTQ files from Metrichor FAST5 files.

Illumina library preparation and sequencing

Nextera XT V2 kit (Illumina) sequencing libraries were prepared using 1.5 ng of amplified cDNA as per manufacturer’s instructions. Samples were multiplexed in batches of a maximum of 16 samples per run and

**Table 1**

Description of samples positive for chikungunya and dengue virus by real-time reverse transcription-PCR with corresponding Illumina mapping data, United Kingdom, 2017 (n = 26 samples)

| Sample | Ct value | Estimated genome copy number in the sample (/mL) | Sample type | Total reads (R1 + R2)b | % reads mapping to reference viral genome | % 20x coverage | % 10x coverage | Reference virusc | Reference size (nts) |
|--------|----------|--------------------------------------------------|-------------|------------------------|------------------------------------------|----------------|----------------|-----------------|-------------------|
| CHIKV 1 | 14.72    | 2.12E+10                                         | Plasma      | 1,113,560              | 78.32                                    | 99.59          | 99.72          | CHIKV           | 11,826            |
| CHIKV 2 | 20.06    | 5.49E+08                                         | Serum       | 1,278,624              | 98.48                                    | 99.14          | 99.47          | CHIKV           | 11,826            |
| CHIKV 3 | 21.41    | 2.18E+08                                         | Plasma      | 1,391,258              | 95.23                                    | 98.86          | 99.37          | CHIKV           | 11,826            |
| CHIKV 4 | 22.74    | 8.76E+07                                         | Plasma      | 888,968                | 91.16                                    | 97.08          | 97.32          | CHIKV           | 11,826            |
| CHIKV 5 | 23.77    | 4.33E+07                                         | Plasma      | 1,357,606              | 97.13                                    | 99.16          | 99.58          | CHIKV           | 11,826            |
| CHIKV 6 | 25.4     | 1.42E+07                                         | Serum       | 3,236,848              | 34.88                                    | 97.80          | 98.40          | CHIKV           | 11,826            |
| CHIKV 7 | 25.76    | 1.11E+07                                         | Plasma      | 3,748,070              | 72.77                                    | 99.04          | 99.56          | CHIKV           | 11,826            |
| CHIKV 8 | 28.17    | 2.13E+06                                         | Plasma      | 1,499,952              | 28.41                                    | 98.96          | 98.22          | CHIKV           | 11,826            |
| CHIKV 9 | 30.08    | 5.76E+05                                         | Serum       | 1,035,026              | 6.66                                     | 95.98          | 98.22          | CHIKV           | 11,826            |
| CHIKV 10| 30.37    | 4.72E+05                                         | Serum       | 1,575,222              | 16.84                                    | 97.39          | 98.01          | CHIKV           | 11,826            |
| CHIKV 11| 30.66    | 3.87E+05                                         | Serum       | 1,143,054              | 15.52                                    | 97.36          | 96.96          | CHIKV           | 11,826            |
| CHIKV 12| 30.95    | 3.17E+05                                         | Serum       | 1,507,380              | 10.93                                    | 96.11          | 96.52          | CHIKV           | 11,826            |
| CHIKV 13| 32.2     | 1.35E+05                                         | Serum       | 1,323,920              | 5.03                                     | 88.47          | 89.38          | CHIKV           | 11,826            |
| CHIKV 14| 32.57    | 1.05E+05                                         | Serum       | 1,479,404              | 21.72                                    | 96.32          | 96.93          | CHIKV           | 11,826            |
| DENV 1 | 16.29    | 4.21E+09                                         | Plasma      | 439,292                | 93.44                                    | 99.51          | 99.58          | DENV 1          | 10,735            |
| DENV 2 | 16.85    | 2.83E+09                                         | Serum       | 513,472                | 92.56                                    | 99.40          | 99.58          | DENV 1          | 10,735            |
| DENV 3 | 17.67    | 1.58E+09                                         | Plasma      | 738,814                | 92.53                                    | 99.58          | 99.58          | DENV 2          | 10,723            |
| DENV 4 | 18.20    | 1.09E+09                                         | Plasma      | 477,368                | 93.97                                    | 98.73          | 99.12          | DENV 2          | 10,723            |
| DENV 5 | 19.73    | 3.67E+08                                         | Serum       | 915554                 | 89.65                                    | 99.14          | 99.40          | DENV 2          | 10,723            |
| DENV 6 | 21.22    | 3.61E+07                                         | Serum       | 3,587,926              | 83.87                                    | 99.68          | 99.69          | DENV 4          | 10,649            |
| DENV 7 | 23.76    | 2.15E+07                                         | Serum       | 4,146,678              | 2.17                                     | 86.99          | 89.13          | DENV 1          | 10,735            |
| DENV 8 | 24.8     | 1.01E+07                                         | Serum       | 777,264                | 69.23                                    | 99.56          | 99.58          | DENV 3          | 10,707            |
| DENV 9 | 25.28    | 7.17E+06                                         | Plasma      | 787,728                | 26.97                                    | 98.77          | 98.81          | DENV 2          | 10,723            |
| DENV 10| 26.98    | 2.15E+06                                         | Serum       | 596,240                | 6.58                                     | 93.47          | 93.97          | DENV 3          | 10,707            |
| DENV 11| 28.69    | 6.39E+05                                         | Serum       | 1,034,698              | 3.73                                     | 94.44          | 94.70          | DENV 1          | 10,735            |
| DENV 12| 31.29    | 1.01E+05                                         | Serum       | 1,374,766              | 0.47                                     | 71.46          | 77.76          | DENV 1          | 10,735            |

CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus.

a The Illumina mapping data presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

b ‘R1 + R2’ indicates paired-end sequencing.

c For DENV the serotype is also indicated.
**Figure 2**
Proportion of reads mapping to the appropriate viral reference sequence and proportion of reference genome sequenced at minimum 20-fold coverage in each chikungunya or dengue virus positive sample, United Kingdom, 2017* (n = 26 samples)

Chikungunya virus samples

Dengue virus samples

Ct: cycle threshold.

*The Illumina data presented in the figure were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

The percentage of total reads mapping to the appropriate reference sequence is plotted in the upper panel. Lower panels display the percentage of the reference genome sequenced to a minimum depth of 20-fold in the Illumina data.
sequenced on a 2x150 bp-paired end Illumina MiSeq run, by Genomics Services Development Unit, PHE.

**Data handling**

BWA MEM v0.7.15 [33] was used to align reads to the following references (GenBank ID): DENV Serotype 1 (NC_001477.1), DENV Serotype 2 (NC_001474.2), DENV Serotype 3 (NC_001475.2), DENV Serotype 4 (NC_002640.1) and CHIKV (NC_004162.2) using -x ont2d mode for Nanopore and MEM defaults for Illumina reads. Samtools v1.4 [34] was used to compute percentage reads mapped and coverage depth. Bedtools v2.26.0 [35] was used to calculate genome coverage at 10x and 20x. Mapping consensuses for Illumina were generated using in-house software QuasiBam [36] and for MinION using a simple pileup with bases called at a minimum depth of 20x and 70% support fraction. Nanopolish variants [24,37] was used in consensus mode to compute an error-corrected consensus sequence from the Rapid kit data. Taxonomic classification was performed using Kraken (0.10.4-beta) [38] and a locally built database populated with all RefSeq bacterial, viral, and archaeal genomes plus additional sequences [39]. De novo assemblies were generated using Spades 3.8.2 [40] in combination with SSPACE Standard v3.0 [41] for Illumina generated sequences and Canu v1.6 [41,42] for Nanopore sequences (settings: corOutCoverage=1,000; genomeSize=12,000; minReadLength=300, minOverlapLength=50).

Consensus sequences for all samples tested are available in Genbank, raw fastq files from 1D2 and 1D data (viral reads only) are deposited in SRA (Both under BioProject PRJNA508296).

**Results**

**Metagenomic Illumina sequencing**

A total of 73 samples tested during 2016 in RIPL diagnostic laboratories, PHE Porton Down, were positive by qRT-PCR for CHIKV, and 368 were positive for DENV. Median Ct for CHIKV was 26.1, for DENV it was 26.8. For each virus, samples representing the range of viral titres seen during 2016 were selected, based on qRT-PCR Ct value (Figure 1). CHIKV samples selected (n = 14) ranged from Ct 14.72 to Ct 32.57, corresponding to 1010 and 105 genome copies per mL of plasma or serum. DENV samples selected (n = 12) ranged from Ct 16.29 to Ct 31.29, corresponding to 10 9 and 105 genome copies per mL (Table 1). To measure the proportion of viral nucleic acid present relative to host/background and assess genome coverage, all samples were processed as described in methods and Illumina sequenced (Table 1). The proportion of reads mapping to viral reference, which were generally concordant with the

| Table 2 |
|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Sample**      | **Ct value** | **cDNA amount used for the library (ng)** | **Sequencing kit (2D kit version)** | **Flow cell (FLO-)** | **1D total bp** | **1D total reads** | **1D mean read length (nt)** | **1D max read length (nt)** |
| CHIKV 1         | 14.7          | 431.5          | SQK-NSK007      | MIN105          | 1.51E+08       | 267,171         | 564             | 92,712          |
| CHIKV 3         | 21.4          | 928.8          | SQK-LSK208      | MIN106          | 1.63E+09       | 1,891,028       | 862             | 99,031          |
| CHIKV 4         | 22.7          | 113.4          | SQK-NSK007      | MIN105          | 1.74E+08       | 216,493         | 805             | 125,387         |
| CHIKV 9         | 30.1          | 212.4          | SQK-LSK208      | MIN106          | 2.12E+09       | 3,481,358       | 608             | 121,711         |
| DENV 1          | 16.3          | 1,626.0        | SQK-NSK007      | MIN105          | 2.42E+08       | 284,622         | 851             | 115,494         |
| DENV 2          | 16.9          | 1,626.0        | SQK-NSK007      | MIN105          | 1.55E+08       | 203,700         | 760             | 52,157          |
| DENV 6          | 21.2          | 475.0          | SQK-LSK208      | MIN106          | 1.22E+09       | 1,377,721       | 886             | 118,733         |
| DENV 11         | 28.7          | 65.8           | SQK-LSK208      | MIN106          | 7.07E+08       | 1,111,566       | 636             | 119,438         |

Ct: cycle threshold.

a The Nanopore data presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

Figure 3 shows percentages of reads mapping to viral reference, which were generally concordant with the
**Figure 3**
Comparison of Nanopore and Illumina results, as to proportions of reads mapping to the appropriate reference viral sequence, and proportions of reference genome sequenced at minimum 20-fold coverage, United Kingdom, 2017\(^4\) (n = 8 samples)

|                  | Chikungunya virus samples | Dengue virus samples |
|------------------|----------------------------|----------------------|
| **Ct Value**     | 14.72                      | 16.29                |
| **Illumina**     | 80                         | 80                   |
| **MinION_TC**    | 60                         | 60                   |
| **Percentage of mapped reads** | 100 | 100 |
| **Percentage 20x coverage** | 80 | 80 |

**Ct:** cycle threshold; **TC:** template/complement.

\(^4\) The Nanopore and Illumina data presented in the figure were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

The percentage of total reads mapping to the appropriate reference sequence is plotted in the upper panel. Lower panels display the percentage of the reference genome sequenced to a minimum depth of 20-fold in the data generated, in dark blue or dark green for the Illumina sequence data, in light blue or light green for Nanopore data (MinION_TC).
Illumina data, although a slight decrease is observed across the range of Ct values. In the Nanopore data, the highest mapped read percentages observed were 85.12% and 72.14% for CHIKV 3 and DENV 2 respectively, compared with 95.23% and 92.56% in the Illumina data from the same samples. While in high Ct samples the viral proportion drops to 4.08% for CHIKV 9 and 2.90% for DENV 11, from 6.66% and 3.73% in the Illumina data.

Despite the decrease in proportion of mapped viral reads, comparable genome coverage is observed at both 20x and 10x (Figure 3, Table 3) and is even increased compared with Illumina data at lower viral titres, e.g. 100% at 20x for CHIKV 9 compared with 95.98% in the Illumina data and 95.25% for the high Ct DENV 11 sample, which generated 94.44% coverage from the Illumina data. Average read lengths in Nanopore data ranged from 564 to 886 bp (Table 2).

Figure 4 shows coverage depth of reads mapped across the relevant genome for each sample sequenced by both Illumina and Nanopore. Read levels are not normalised thus actual depth is a function of total reads sequenced, but the pattern of coverage seen is highly similar suggesting it is more dependent upon the SISPA methodology than sequencing library preparation. From Nanopore consensus genome sequences, between 99.93% and 100% of bases called per sample agreed with the Illumina generated sequence.

| Sample | Ct value | Total reads | % reads mapping to appropriate viral sequence | % 20x coverage | 20x genome length (nt) | % 10x coverage | Reference | Reference size (nt) | Max de novo contig (nt) |
|--------|----------|-------------|----------------------------------------------|----------------|-----------------------|----------------|-----------|-------------------|---------------------|
| CHIKV 1 | 14.7     | 267,171     | 65.1                                         | 98.57          | 11,658                | 99.2           | CHIKV     | 11,826            | 5,263               |
| CHIKV 3 | 21.4     | 1,891,028   | 85.1                                         | 99.76          | 11,798                | 99.9           | CHIKV     | 11,826            | 10,793              |
| CHIKV 4 | 22.7     | 216,493     | 11.6                                         | 94.11          | 11,130                | 97.2           | CHIKV     | 11,826            | 4,256               |
| CHIKV 9 | 30.08    | 3,481,358   | 4.08                                         | 100            | 11,826                | 100            | CHIKV     | 11,826            | 9,860               |
| DENV 1  | 16.3     | 284,622     | 71.3                                         | 99.9           | 10,719                | 99.9           | DENV 1    | 10,735            | 8,281               |
| DENV 2  | 16.9     | 203,700     | 72.1                                         | 99.6           | 10,692                | 99.6           | DENV 1    | 10,735            | 10,157              |
| DENV 6  | 21.2     | 1,377,721   | 71.1                                         | 99.9           | 10,634                | 99.9           | DENV 4    | 10,649            | 7,877               |
| DENV 11 | 28.7     | 1,111,566   | 2.9                                          | 95.3           | 10,226                | 96.3           | DENV 1    | 10,735            | 4,699               |

CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus.

a The Nanopore data presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

b For DENV the serotype is also indicated.

Kraken analysis also allowed for the identification of a DENV coinfection in sample CHIKV 3, the consensus sequence of which was unique in the sample set, eliminating cross-contamination from the DENV positive samples as potential source. Kraken classified 0.08% of Illumina reads and 0.15% of MinION reads as DENV. Using reference mapping to validate the finding, 0.22% of Illumina reads and 0.43% of MinION reads mapped to a DENV-1 reference genome. Genome coverage at 20x of 99.73% and 95.99% was achieved for the primary CHIKV and secondary DENV coinfection respectively, with a single MinION flow cell.

De novo assembly
De novo assembly of the data was attempted using Canu [42] and contigs identified using Basic Local Alignment Search Tool against a Nt database (BLASTn). Table 3 lists the longest viral contig length identified in each sample, ranging from 4.2 Kb (36% of reference genome size) to 10.8 Kb (91%) for CHIKV and 4.7 Kb (44%) to 10.1 Kb (95%) for DENV. Identification of the pathogen present without prior knowledge would have therefore been possible for all samples.
We repeated the sequencing of the coinfected CHIKV sample using the MinION 1D\(^2\) (SQK-LSK308) and Rapid (SQK-RBK001) kits, currently the most accurate and the fastest library preparation kits available, respectively. Using the 1D\(^2\) kit 74.5% of reads generated mapped to CHIKV and 0.37% to DENV, while from the Rapid kit the result was 66.26% and 0.29% respectively (both lower than observed in the 2D chemistry). Coverage at 20x for CHIKV was above 99% for both kits, and for DENV was 95.04% from the 1D\(^2\) and 81.09% from the Rapid kit (Table 4). Coverage depth pattern across the genome for both viruses (Figure 6) was similar for all library kits tested. Near-maximum coverage for both viruses was obtained within 30 min with the 2D kit, 8 min with the 1D\(^2\) kit and 85 min with the Rapid kit (Supplementary Figure 1). De novo assembly (Table 4) produced best CHIKV contigs of 10.7, 11.3 and 11.4 Kb for the 2D, 1D\(^2\) and Rapid libraries respectively and the longest contigs generated for DENV were 7.5, 2.2 and 4.2 Kb.

The 1D data from the Rapid kit was sufficient to call a consensus from 11,647/11,826 bases of the CHIKV reference with 179/11,826 bases called as ambiguous or too low coverage. All bases called were concordant with the Illumina consensus. A polishing step using Nanopolish [37] with a subset of the mapped reads (ca100x coverage depth) significantly reduced ambiguous calls to 90/11,826, introducing a single disagreement with the Illumina consensus (99.99% concordance). Despite considerably greater read depth, the 1D\(^2\) kit called only

---

**Figure 4**

Coverage depth across the chikungunya or dengue viral genome, United Kingdom, 2017* (n = 8 samples)

---

*Ct: cycle threshold.

* The Nanopore and Illumina data presented in the figure were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

Each graph corresponds to a given sample, defined by its Ct value. Read depth (y-axis) across the genome (x-axis) following reference alignment is shown. Illumina coverage is shown in darker blue and darker green for chikungunya and dengue virus positive samples respectively. Nanopore (MinION) coverage is indicated in lighter blue or lighter green for chikungunya and dengue virus positive samples respectively. Total depth has not been normalised; comparison is to show overall pattern of coverage is highly similar across the methods. Dotted horizontal line indicates depth of 20x coverage, used for consensus calling.

---

**Updated MinION library kits**

We repeated the sequencing of the coinfected CHIKV 3 sample using the MinION 1D\(^2\) (SQK-LSK308) and Rapid (SQK-RBK001) kits, currently the most accurate and the fastest library preparation kits available, respectively. Using the 1D\(^2\) kit 74.5% of reads generated mapped to CHIKV and 0.37% to DENV, while from the Rapid kit the result was 66.26% and 0.29% respectively (both lower than observed in the 2D chemistry). Coverage at 20x for CHIKV was above 99% for both kits, and for DENV was 95.04% from the 1D\(^2\) and 81.09% from the Rapid kit (Table 4). Coverage depth pattern across the genome for both viruses (Figure 6) was similar for all library kits tested. Near-maximum coverage for both viruses was obtained within 30 min with the 2D kit, 8 min with the 1D\(^2\) kit and 85 min with the Rapid kit (Supplementary Figure 1). De novo assembly (Table 4) produced best CHIKV contigs of 10.7, 11.3 and 11.4 Kb for the 2D, 1D\(^2\) and Rapid libraries respectively and the longest contigs generated for DENV were 7.5, 2.2 and 4.2 Kb.

The 1D data from the Rapid kit was sufficient to call a consensus from 11,647/11,826 bases of the CHIKV reference with 179/11,826 bases called as ambiguous or too low coverage. All bases called were concordant with the Illumina consensus. A polishing step using Nanopolish [37] with a subset of the mapped reads (ca100x coverage depth) significantly reduced ambiguous calls to 90/11,826, introducing a single disagreement with the Illumina consensus (99.99% concordance). Despite considerably greater read depth, the 1D\(^2\) kit called only
Discussion
These results clearly show that there are considerable levels of viral nucleic acid present in a large proportion of CHIKV and DENV qRT-PCR positive clinical samples, and demonstrate that relatively modest metagenomic sequencing is capable of elucidating significant portions of viral genome even for samples with Ct values at the higher end of clinical range. A decreased Ct value coincided with an increased proportion of viral reads, with a considerable level of variation between samples, likely because of the total level of non-viral host/background nucleic acid present due to variability between patients or in sample handling during collection, storage and testing. For example, the two lowest viral titre CHIKV samples (13 and 14) have similar Ct values (32.2 and 32.57) but varied significantly in the proportion of viral reads (5.03% and 21.72%). The 5.03% viral reads in CHIKV13 is the lowest for CHIKV, yet still sufficient to generate 88.5% of the CHIKV genome at 20x depth from just ca 662,000 paired-end Illumina reads. This amount of genomic information is highly informative and further sequencing would likely increase coverage. Only seven of the 73 total CHIKV diagnostic samples tested in 2016 had a Ct greater than 32.2 (including sample CHIKV14) (Table 1), which suggests that for the majority (> 90%) of CHIKV PCR positive samples, viral load is sufficient for genome sequencing directly from patient samples without further viral enrichment beyond a simple DNAse digestion (Figure 1). The lowest viral read proportion observed in the DENV samples was 0.47% in DENV12, Ct 31.29, which generated 71.5% coverage at 20x depth (increased to 77.8 at 10x

**Figure 5**
Kraken classification of reads from metagenomic sequencing in (A) chikungunya and (B) dengue real-time reverse transcription-PCR positive samples, United Kingdom, 2017 (n = 8 samples)

| Illumina | MiniON |
|-----------------|-----------------|
| Chikungunya | Chikungunya |
| Other viruses | Other viruses |
| Bacteria | Bacteria |
| Archaea/eukaryota | Archaea/eukaryota |
| Unclassified | Unclassified |

Ct: cycle threshold.

*Read taxonomic classification using Kraken was conducted in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.*

Kraken classification distribution comparison for Illumina (cross-hatched) and Nanopore data. Reads grouped as either chikungunya virus (blue in panel A), dengue virus (green in panel B), other viruses (brown), archea/eukaryota (orange), bacteria (brown) or unclassified (grey).
depth) from just 687,000 paired end Illumina reads and allowed for DENV serotype identification. Only 62 of 368 DENV cases in 2016 had a higher Ct, predicting that >80% of PCR positive DENV samples have a viral load sufficient for genome sequencing (Figure 1). These estimates are based on Ct range distribution from a single year, results may vary from year to year.

The high yield of viral sequences from clinical CHIKV and DENV samples make the exciting prospect of metagenomic MinION viral whole-genome-sequencing feasible, even for lower viral titre samples. Evaluating this on a representative subset of our samples demonstrates that viral read proportions are in general agreement with that seen for Illumina sequencing, predicting a similar proportion of qRT-PCR positive patient samples would be suitable for direct metagenomic sequencing on the MinION. Differences in precise proportions of viral reads seen between Illumina and MinION are likely due to inter-library variation. Differences in genome coverage achieved are due to both differences in total reads generated per sample (not normalised between platforms) as well as differences in average read length. Of the samples tested on the MinION, the lowest titre samples CHIKV 9 and DENV 11 both generated near complete genome coverage.

We repeated the sequencing of the coinfected CHIKV 3 sample using the MinION 1D (SQK-LSK308) and Rapid (SQK-RBB001) kits. A reduction in viral proportion of total reads was observed compared with the 2D kit, which may be due partly to the extended storage time of the original samples before retesting. In the case of the 1D kit, the lower proportion was outweighed by a substantial increase in total data generated per flow cell (5 M vs 1.8 M reads). For the Rapid kit, the total data produced should be considered in the light of the greatly simplified sample workflow and turnaround-time.

The use of metagenomics to elucidate genomic sequences of RNA viruses directly from clinical samples has several obvious benefits in public health applications. The primary benefit over targeted methods is the hypothesis-free nature of the assay, which allows identification and genomic characterisation of novel or unexpected RNA viral agents, either as primary or coinfectants (demonstrated here in the CHIKV/DENV co-infection sample), without any prior clinical knowledge. It also removes the need for laboratory optimisation of targeted methods, such as primer or bait-probe design and testing, and is not subject to escape mutations in target sites that afflict targeted sequencing and diagnostic methods. This issue particularly relevant for highly diverse RNA viruses, such as Lassa virus, which are difficult to assess using targeted methods, without regular reappraisal [43].

The principal limitation of the metagenomic approach is the limit of detection. The data generated here show that viral titres as low as \(10^5\) are sufficient for significant genome recovery by this method, but ZIKV is a recent example of a pathogen typically present at lower clinical titres, for which targeted methods are an absolute requirement [22,23]. For diagnostic purposes qRT-PCR has a lower limit of detection, provided the target site is conserved in the pathogen isolate tested. Clearly no single method is most suitable for both detection and genotyping of all pathogens and each has a role to play in differing circumstances.

The ability to generate genomic data directly from patient samples is clearly of great benefit to public health programmes. The ability to identify novel RNA viral agents and assess their impact on public health is of great value.

### Table 4

Comparison of Nanopore mapping data across library kits, United Kingdom, 2017\(^a\) (n = 8 samples)

| Platform | Kit information | Flow cell (FLO) | Virus identified | Total reads (nt) | % reads mapping | % 20x coverage | % 10x coverage | Reference\(^b\) | Reference size (nt) | Max de novo contig (nt) |
|----------|-----------------|-----------------|------------------|------------------|----------------|----------------|---------------|-----------------|----------------------|-------------------------|
| Illumina | Nextera XT      | NA              | CHIKV            | 1,391,258        | 95.23          | 98.86          | 99.37         | CHIKV          | 11,826               | 7,321                   |
| Illumina | Nextera XT      | NA              | DENV             | 1,391,258        | 0.22           | 63.66          | 77.82         | DENV           | 10,735               | 6,613                   |
| MinION 2D| SQK-LSK208      | MIN106          | CHIKV            | 1,891,028        | 85.12          | 99.73          | 99.91         | CHIKV          | 11,826               | 10,793                  |
| MinION 2D| SQK-LSK208      | MIN106          | DENV             | 1,891,028        | 0.43           | 95.99          | 96.09         | DENV           | 10,735               | 7,549                   |
| MinION 1D\(^a\)| SQK-LSK308    | MIN107          | CHIKV            | 5,080,906        | 74.50          | 99.04          | 100           | CHIKV          | 11,826               | 11,169                  |
| MinION 1D\(^a\)| SQK-LSK308    | MIN107          | DENV             | 5,080,906        | 0.37           | 95.04          | 96.42         | DENV           | 10,735               | 2,199                   |
| MinION Rapid | SQK-RBB001   | MIN106          | CHIKV            | 611,110          | 66.26          | 99.66          | 99.68         | CHIKV          | 11,826               | 11,473                  |
| MinION Rapid | SQK-RBB001   | MIN106          | DENV             | 611,110          | 0.29           | 81.09          | 90.83         | DENV           | 10,735               | 4,227                   |

CHIKV: chikungunya virus; Ct: cycle threshold; DENV: dengue virus. NA: not applicable.

\(^a\) Results presented in the table were obtained in 2017 on samples that had been collected and found positive for chikungunya or dengue virus by real-time reverse transcription-PCR in 2016.

\(^b\) For DENV the serotype is also indicated.
health (reviewed in detail [44]). It can be used in a routine surveillance capacity or early during suspected outbreaks to link related cases who may be missed by traditional epidemiology [45] and identify outbreak cases distinct from typically circulating seasonal strains, which is key in regions endemic for the pathogen in question. The use of whole genome sequences offers the greatest precision for these applications, compared with typing methods based on specific genomic regions [44]. Whole genome sequencing on a portable device allows this information to be generated rapidly and within the affected region [24], enabling timely identification of an outbreak, or allaying fears of a potential one if cases are not linked. Furthermore mutations relating to viral drug resistance or pathogenicity can be monitored [44]. Therefore the ability to generate near-complete viral genome sequences directly from clinical samples on a portable sequencing device has many potential applications.

Conclusions

We demonstrate that across the clinically relevant range of viral loads an unexpectedly high proportion of reads generated metagenomically from CHIKV and DENV clinical samples are viral in origin. Therefore metagenomic sequencing provides an effective approach for the analysis of CHIKV and DENV genomes directly from the majority of qRT-PCR positive serum and plasma samples, without the need for culture or viral nucleic acid enrichment beyond a simple DNA digestion. We demonstrate this is equally possible on the Oxford Nanopore MinION, making metagenomic
whole genome sequencing potentially feasible in the field.

Acknowledgements

This work was funded via an NIHR HPRU in Emerging and Zoonotic Infections PhD studentship awarded to L. Kafetzopoulou. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health. Oxford Nanopore Technologies provided some reagents free of charge and funded author conference attendance.

Conflict of interest

Oxford Nanopore Technologies provided some reagents free of charge and funded author conference attendance.

Authors’ contributions

Performed experiments: LEK, KL, AC, DC
Performed data analysis: LEK, KE, STP
Design of study: LEK, EA, JO, RH, JAH, MWC, RV, STP
Wrote the manuscript: LEK, STP

All authors reviewed the manuscript.

References

1. Papa A. Emerging arboviral human diseases in Southern Europe. J Med Virol. 2017;89(8):1315-22. https://doi.org/10.1002/jmv.24803 PMID: 28522004
2. Gould E, Pettersson J, Higgs S, Charrel R, de Lamballerie X. Chikungunya: a re-emerging virus. Lancet. 2012;379(9810):662-71. https://doi.org/10.1016/S0140-6736(11)6028X PMID: 22100854
9. Patterson J, Sammon M, Garg M, Dengue, Zika and Chikungunya: Emerging Arboviruses in the New World. West J Emerg Med. 2016;17(6):671-9. https://doi.org/10.5811/westjem.2016.9.30904 PMID: 27833670
10. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. Lancet.

2012;379(9810):662-71. https://doi.org/10.1016/S0140-6736(11)6028X PMID: 22100854
11. Simmons CP, Farrar JJ, van Vinn Chau N, Wills B, Dengue. N Engl J Med. 2012;366(15):1423-32. https://doi.org/10.1056/NEJMra1110269 PMID: 22641122
12. Furuya-Kanamori L, Liang S, Milanovich G, Soares Magalhaes RJ, Clements ACA, Hu W, et al. Co-distribution and co-infection of chikungunya and dengue viruses. BMC Infect Dis. 2016;16(1):84. https://doi.org/10.1186/s12879-016-1417-2 PMID: 26936191
13. Perera-Leconin M, Lupertlop N, Surasombatpatta P, Liégeois F, Hamel R, Thongrungkit S, et al. Dengue and Chikungunya Co-infection – The Emergence of an Underestimated Threat. In: Rodrigues-Morales AI, editor. Current Topics in Chikungunya. InTech; 2016.
14. Omarjee R, Prat C, Flusin O, Boucari S, Tenebray B, Merle O, et al. Importance of case definition to monitor ongoing outbreak of chikungunya virus on a background of actively circulating dengue virus, St Martin, December 2013 to January 2014, Euro Surveill. 2014;19(3):2073. https://doi.org/10.2807/1560-797X.ES.2014.19.3.2073 PMID: 24873598
15. Brito CAA, Azevedo F, Cordeiro MT, Marques ETA Jr, Franchi RO. Central and peripheral nervous system involvement caused by Zika and chikungunya coinfection. PLoS Negl Trop Dis. 2017;11(7):e0005879. https://doi.org/10.1371/journal.pntd.0005879 PMID: 28112347
16. Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis. 2009;9(9):562-72. https://doi.org/10.1016/S1473-3099(09)70383-6 PMID: 20285712
17. Maksymowych W, Macarewicz J, Chudacki J, Marszalek A, Szklarczyk D, Wilusz J. Single-stranded RNA viruses: emerging threats to human and animal health. J Virol. 2015;89(16):8688-91. https://doi.org/10.1128/JVI.00195-15 PMID: 26066101
18. Coetzee MA, Terblanche JS. Dengue virus, St Martin, December 2013 to January 2014, Euro Surveill. 2014;19(3):2073. https://doi.org/10.2807/1560-797X.ES.2014.19.3.2073 PMID: 24873598
19. Towner JS, Sealy TK, Khristova ML, Albarillo CG, Conlan S, Reeder SA, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda with hemorrhagic fever in the United States. Nature. 2017;546(7658):401-5. https://doi.org/10.1038/nature22400 PMID: 28538734
20. Metsky HC, Matranga CB, Wohl S, Schaffner SF, Freije K, Genzel GH, et al. MinION as part of a biomedical rapidly deployable laboratory. J Biotechnol. 2017;228:1-13. https://doi.org/10.1016/j.jbiotec.2017.06.001 PMID: 28785601
21. Batovska J, Lynch SE, Rodoni BC, Sawbridge TI, Cogan NO. Metagenomics: a synthetic approach. Gigascience. 2017;6(3):1-13. https://doi.org/10.1093/gigascience/gix007 PMID: 28011234
22. Walter MC, Zwirglmaier K, Vette P, Holowachuk SA, Stoecker VL, Vande Wiele T. Metagenomic arbovirus detection using MinION nanopore sequencing. Metagenome Res. 2013;1:100. https://doi.org/10.1016/j.metagenome.2013.03.003 PMID: 23862814
23. Quick J, Loman NJ, Duraffour S, Simpson JT, Severi E, Cowley LM, et al. Real-time, portable genome sequencing for Ebola virus detection from clinical samples. Nat Protoc. 2017;12(6):1261-76. https://doi.org/10.1038/nprot.2017.066 PMID: 28538727
24. Quick J, Grubaugh ND, Pullan ST, Claridge IM, Smith AD, Gangavarapu K, et al. Genomic epidemiology reveals multiple introductions of Zika virus into the United States. Nature. 2017;546(7658):406-10. https://doi.org/10.1038/nature22401 PMID: 28538734
25. Grubaugh ND, Loman NJ, Koeppen J, Kang L, Kraemer MU, Dugas G, Tan AL, Gangavarapu K, et al. Genomic epidemiology reveals multiple introductions of Zika virus into the United States. Nature. 2017;546(7658):401-5. https://doi.org/10.1038/nature22400 PMID: 28538734
26. Noseworthy M, Fournier S, Trattner C, Leclerc A, Nguyen D, Barker C, et al. Establishment and cryptic transmission of Zika virus in North America. Nature. 2017;546(7658):401-5. https://doi.org/10.1038/nature22401 PMID: 28538734
27. Batovska J, Lynch SE, Rodoni BC, Sawbridge TI, Cogan NO. Metagenomic arbovirus detection using MinION nanopore sequencing. Metagenome Res. 2013;1:100. https://doi.org/10.1016/j.metagenome.2013.03.003 PMID: 23862814
28. Greninger AL, Naccache SN, Federman S, Yu G, Mbala P, Bres KV. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg Infect Dis. 2008;14(3):442-5. https://doi.org/10.3201/eid1403.070720 PMID: 18325255
29. Vos T, Allen C, Arora M, Barber RM, Bhatta ZA, Brown A, et al. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-620. https://doi.org/10.1016/S0140-6736(16)31686-6 PMID: 27733282
30. Patterson J, Sammon M, Garg M, Dengue, Zika and Chikungunya: Emerging Arboviruses in the New World. West J Emerg Med. 2016;17(6):671-9. https://doi.org/10.5811/westjem.2016.9.30904 PMID: 27833670
31. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. Lancet.
29. Sardi SI, Somasekar S, Naccache SN, Bandeira AC, Tauro LB, Campos GS, et al. Coinfections of Zika and Chikungunya Viruses in Bahia, Brazil, Identified by Metagenomic Next-Generation Sequencing. J Clin Microbiol. 2016;54(9):2348-53. https://doi.org/10.1128/JCM.00877-16 PMID: 2741390

30. Drosten C, Göttig S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40(7):2373-30. https://doi.org/10.1128/JCM.40.7.2373-2380.2002 PMID: 12089242

31. Edwards CJ, Welch SR, Chamberlain J, Hewson R, Tolley H, Cane PA, et al. Molecular diagnosis and analysis of Chikungunya virus. J Clin Virol. 2007;39(4):271-5. https://doi.org/10.1016/j.jcv.2007.05.008 PMID: 17627877

32. Loman NJ, Quinlan AR. Poretools: a toolkit for analyzing nanopore sequence data. Bioinformatics. 2014;30(23):3399-401. https://doi.org/10.1093/bioinformatics/btu555 PMID: 2516291

33. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-60. https://doi.org/10.1093/bioinformatics/btp324 PMID: 1945168

34. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. 1000 Genome Project Data Processing Subgroup. The Sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(6):2078-9. https://doi.org/10.1093/bioinformatics/btp352 PMID: 19506943

35. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841-2. https://doi.org/10.1093/bioinformatics/btp033 PMID: 2010278

36. Penedos AR, Myers R, Hadef B, Aladin F, Brown KE. Assessment of the Utility of Whole Genome Sequencing of Measles Virus in the Characterisation of Outbreaks. PLoS One. 2015;10(11):e0143081. https://doi.org/10.1371/journal.pone.0143081 PMID: 26569100

37. Loman NJ, Quick J, Simpson JT. A complete bacterial genome assembled de novo using only nanopore sequencing data. Nat Methods. 2015;12(8):733-5. https://doi.org/10.1038/nmeth.3444 PMID: 26076426

38. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 2014;15(3):R46. https://doi.org/10.1186/s13059-014-0346-8 PMID: 24580807

39. Lewandowski K, Bell A, Miles R, Carne S, Wooldridge D, Manso C, et al. The Effect of Nucleic Acid Extraction Platforms and Sample Storage on the Integrity of Viral RNA for Use in Whole Genome Sequencing. J Mol Diagn. 2017;19(2):303-12. https://doi.org/10.1016/j.jmoldx.2016.10.005 PMID: 28041870

40. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19(5):455-77. https://doi.org/10.1089/cmb.2012.0021 PMID: 22506599

41. Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. Scaffolding pre-assembled contigs using SSPACE. Bioinformatics. 2011;27(4):578-9. https://doi.org/10.1093/bioinformatics/btr683 PMID: 21149342

42. Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. Genome Res. 2017;27(5):722-36. https://doi.org/10.1101/gr.215087.116 PMID: 28298431

43. Andersen KG, Shapiro BJ, Matranga CB, Sealfon RS, Moses LM, et al. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell. 2015;162(4):738-50. https://doi.org/10.1016/j.cell.2015.07.020 PMID: 26276630

44. Houldcroft CJ, Beale MA, Breuer J. Clinical and biological insights from viral genome sequencing. Nat Rev Microbiol. 2017;15(3):183-92. https://doi.org/10.1038/nrmicro.2016.182 PMID: 28090077

45. Keita M, Duraffourg S, Loman NJ, Rambaut A, Diallo B, Magassouba N, et al. Unusual Ebola Virus Chain of Transmission, Conakry, Guinea, 2014-2015. Emerg Infect Dis. 2016;22(2):2149-52. https://doi.org/10.3201/eid2212.160847 PMID: 27869596